Evexia Lifecare to buy 60% of Reponex Pharma for $6.94M
What's the deal? Evexia LifecareDealroom has a profile for this one. Try Dealroom →'s board has approved acquiring up to 60% of Reponex Pharmaceuticals A/SDealroom has a profile for this one. Try Dealroom → for US$9.12M, the Indian company said after its October 7, 2026 board meeting. The deal gives Evexia a controlling stake and expands its pharmaceutical footprint.
How it's structured: Evexia will subscribe to 20,997,180 fresh equity shares of Reponex at US$0.43 per share, paid entirely in cash. After allotment, existing shareholders keep the remaining 40%, and Reponex's paid-up share capital rises to 34,995,300 shares.
Why an equity route? The company described the transaction as an equity investment, not an asset transfer or slump sale, and said it is unrelated to promoter group companies. It may be completed in one or more tranches.
How it's funded: Evexia's board approved in principle a capital raise through instruments including equity shares, warrants, debentures, or debt securities, via a preferential or rights issue. Final size, quantum, and timing are to be decided later, depending on market conditions.
What could go wrong? Completion depends on definitive agreements and pending statutory and regulatory approvals. The company has not named a completion date or disclosed committed financing, leaving open questions on dilution and leverage.
The signal: The move follows a September 7, 2026 preliminary approval, when Evexia empowered two directors to run due diligence and valuation without disclosing a price. The latest step formalises the price and stake, signalling a measured consolidation play as the company builds scale in pharma.
Read more: multibagg.ai
Image credit: foteih
